Introduction {#s1}
============

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological cancers in many countries ([@B1]--[@B3]). Most patients with chemotherapy-sensitive disease develop chemotherapy-resistant relapse after undergoing several lines of therapy. Maintenance therapy with targeted agents following primary cytoreductive surgery and chemotherapy to extend the progression-free interval (PFI) is promising for improving EOC prognosis ([@B4], [@B5]). Bevacizumab (BEV) can improve overall response rates in front-line or relapse therapy settings ([@B5], [@B6]). Front-line chemotherapy with BEV throughout improved progression-free survival (PFS) in the GOG-218 ([@B7]) and ICON7 ([@B8]) trials and prolonged overall survival (OS) in GOG-218 stage IV and ICON7-defined high-risk patients ([@B9], [@B10]). In total, 52 and 39% reductions in the risk of progression or death by adding BEV to chemotherapy were observed in platinum-sensitive recurrent EOC in the OCEANS ([@B11]) and GOG-213 ([@B12]) trials, respectively. A 52% reduction in the risk of progression or death was seen in platinum-resistant recurrent EOC in AURELIA ([@B13]). However, the secondary endpoint in extending OS was not achieved ([@B9], [@B11]--[@B13]).

BEV-related adverse effects (AEs) are well understood ([@B7], [@B8], [@B11]--[@B14]). Patients treated with BEV experienced a higher incidence of hypertension, proteinuria, gastro-intestinal (GI) and non-central nervous system (non-CNS) bleeding events, and thromboembolism (TE) than those not treated with BEV.

Based on these large clinical trials, BEV is used as the standard of care in EOC patients in many countries. However, the medical cost of adding BEV to chemotherapy may make this treatment unaffordable for EOC patients if it is not covered by the national health insurance (NHI). Moreover, the disease status in real-world patients is much more complex than that in clinical trials. Some real-world investigations have focused on the impact on PFS and AEs when BEV is added to front-line treatment ([@B15]--[@B17]). More real-world data to compare BEV effects on prognosis in recurrent EOCs or AEs between patients with or without prior BEV treatment are needed to assess cost-effectiveness ([@B18]--[@B20]).

Therefore, our study focused on EOC/tubal cancer (TC)/primary peritoneal cancer (PPC) patients who underwent front-line paclitaxel-carboplatin chemotherapy ± BEV or those with recurrent/persistent disease who underwent BEV ± chemotherapy. Our primary aim was to describe the correlation between clinico-pathological factors and physician-patient shared decision-making (SDM), as well as the survival benefits of adding BEV to front-line chemotherapy. Secondarily, we aimed to determine the safety of combination regimens of BEV plus chemotherapy, with or without prior BEV use. We aimed to identify advanced-stage or high-risk patients who may have a more favorable outcome in the front-line setting and predict which subgroup has a better prognosis after adding BEV.

Patients and Methods {#s2}
====================

Participants
------------

The clinical research protocol was approved by the National Cheng Kung University Hospital Institutional Review Board (Protocol No. A-ER-108-119). The study was performed in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study and the difficulties to access to patients. The study flow chart regarding patient inclusion is illustrated in [Figure 1](#F1){ref-type="fig"}. Patients with histologically proven EOC/TC/PPC were considered eligible if they received front-line platinum-based chemotherapy as preoperative (neoadjuvant) or postoperative (adjuvant) therapy (Cohort 1) or if their relapsed diseases were treated with BEV ± any chemotherapy (Cohort 2) between January 1, 2011 and August 31, 2019.

![Study flow chart. **(A)** Cohort 1 patients underwent first-line paclitaxel-carboplatin chemotherapy with or without bevacizumab (BEV). **(B)** Cohort 2 patients with relapsed or persistent disease treated with BEV ± chemotherapy. Patients were also categorized as groups with progression-free interval (PFI) \<6 and ≥6 m.](fonc-10-01095-g0001){#F1}

Study Methods
-------------

Medical records were reviewed for patients\' clinical characteristics, treatment-related AEs, and treatment outcomes. Patients without postoperative front-line chemotherapy owing to any reason and those who had non-paclitaxel-platinum doublet were excluded. Cancer stage was determined according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO). Residual nodules \<1 cm and ≥1 cm were categorized as "optimal" and "suboptimal," respectively. Cancer progression was defined based on the objective Response Evaluation Criteria in Solid Tumors 1.1 or the Gynecologic Cancer InterGroup (GCIG) definition. Our high-risk patients for progression was defined as FIGO stage IV, inoperable or macroscopic residuum \>1 cm FIGO stage III disease, based on ICON7 definition ([@B10]). The last record was retrieved on August 31, 2019. AE severity was graded according to the Common Terminology Criteria for Adverse Events, version 4.03. OS was calculated based on the diagnosis date. PFS and PFI were determined using the date of last contact or progression after front-line chemotherapy. PFI \<6 months (m) and ≥6 m were categorized as "platinum-resistant" and "platinum-sensitive," respectively. "PFS2-PFS" was calculated based on the date of the first relapse or persistence to the next progression or death.

Statistical Analysis
--------------------

Data were analyzed using SPSS (version 19.0; SPSS Inc., Chicago, IL, USA) ([@B21]). Interval variables are presented as means ± standard deviations. Differences between groups were tested using the Mann--Whitney U test. Frequency distributions between categorical variables were compared using Pearson *X*^2^ or Fisher\'s exact tests. Survival was estimated using the Kaplan--Meier method and compared using log-rank tests. P \< 0.05 (two-sided) was considered statistically significant. Cox proportional hazards models were used to estimate hazard ratios (HRs) and confidence intervals (CIs). Possible confounders were included in multivariate analyses. The independent effect of BEV use on survival and disease progression was analyzed in the multivariate analysis.

Results {#s3}
=======

Patient Demographics
--------------------

### Cohort 1 Patients

Newly diagnosed patients (*n* = 381) aged 21--88 years (y) (mean, 53.6 ± 11.4 y) were enrolled. Only 37 patients were aged \>70 y. Most patients (*n* = 359, 94.2%) were diagnosed with EOC; eight (2.1%) were diagnosed with TC and 14 (3.7%) with PPC. Of these, 77 (20.2%) received postoperative paclitaxel-carboplatin doublet plus BEV. A total of 147 (38.6%) were classified as having FIGO stages I--II and 234 (61.4%) as having stages III--IV; 116 (30.4%) patients were in the high-risk subgroup. More than half of the patients (*n* = 203, 53.3%) had serous histology, 108 (28.3%) had clear cell carcinoma (CCC) histology, 39 (10.2%) had endometrioid histology, and 20 (5.2%) had mucinous histology. The other histological types included transitional cell carcinoma and poorly-differentiated adenocarcinoma. The median follow-up period was 33.7 m (range 1.7--99.9 m).

BEV dosage was 7.5--15.1 (mean, 9.2 ± 1.5) mg/kg, and number of treatment cycles was 1--17 (mean 7.9 ± 5.0). The dosage was \<10 mg/kg/cycle in 71.4% of patients, and \<10 cycles were used in 76.6% of patients. BEV dosages were similar between stage III--IV (*n* = 67) and the high-risk patients (*n* = 37) (mean, 9.3 ± 1.6 and 9.3 ± 1.8 mg/kg, respectively). There was no difference in the number of treatment cycles between these groups (mean, 7.9 ± 5.0 and 7.9 ± 4.6 cycles, respectively). During follow-up, 45 patients (58.4%) in the chemotherapy plus BEV group developed progressive disease, and 22 (28.6%) died; 156 patients (51.3%) in the chemotherapy alone group had progressive disease, and 114 patients (37.5%) died.

Relationships between whether BEV was added to chemotherapy and clinicopathological factors are presented in [Table 1](#T1){ref-type="table"}. Women who received chemotherapy plus BEV, had significantly more advanced stage (87.0 vs. 54.9%), serous histology (66.2 vs. 50.0%), preoperative chemotherapy (9.1 vs. 1.6%), residual tumor size ≥1 cm (32.5 vs. 19.7%), and triweekly delivery of postoperative chemotherapy (89.6 vs. 71.1%), when compared with patients treated with chemotherapy alone.

###### 

Clinico-pathological characteristics of newly diagnosed patients (Cohort 1) (*N* = 381).

  -------------------------------------------------------------------------------------------------------------------------------------------
                                                    **Chemotherapy Alone *N* = 304**   **Chemotherapy plus bevacizumab *N* = 77**   ***P***
  ------------------------------------------------- ---------------------------------- -------------------------------------------- ---------
  Age (mean ± SD)                                   53.6 ± 11.0                        53.5 ± 11.0                                  0.850

  Cancer origin                                                                                                                     0.315

      Ovary                                         289\                               70\                                          
                                                    (95.1)                             (90.9)                                       

      Tube                                          6\                                 2\                                           
                                                    (2.0)                              (2.6)                                        

      Peritoneum                                    9\                                 5\                                           
                                                    (3.0)                              (6.5)                                        

  Stage                                                                                                                             \<0.001

      Early                                         137\                               10\                                          
                                                    (45.1)                             (13.0)                                       

          I                                         98\                                6\                                           
                                                    (32.3)                             (7.8)                                        

          II                                        39\                                4\                                           
                                                    (12.8)                             (5.2)                                        

      Advanced                                      167\                               67\                                          
                                                    (54.9)                             (87.0)                                       

          III                                       135\                               44\                                          
                                                    (44.4)                             (57.1)                                       

          IV                                        32\                                23\                                          
                                                    (10.5)                             (29.9)                                       

  Histology                                                                                                                         0.013

      Serous                                        152\                               51\                                          
                                                    (50.0)                             (66.2)                                       

      Non-serous                                    152\                               26\                                          
                                                    (50.0)                             (33.8)                                       

          Clear cell                                91\                                17\                                          
                                                    (29.9)                             (22.1)                                       

          Endometrioid                              34\                                5\                                           
                                                    (11.2)                             (6.5)                                        

          Mucinous                                  18\                                2\                                           
                                                    (5.9)                              (2.6)                                        

          Other type                                9\                                 2\                                           
                                                    (3.0)                              (2.6)                                        

  Tumor grade                                                                                                                       0.143

      Low (grade 1)                                 11\                                3\                                           
                                                    (3.6)                              (3.9)                                        

      High (grade 2 or 3)                           284\                               73\                                          
                                                    (93.4)                             (94.8)                                       

      Unspecified                                   9\                                 1\                                           
                                                    (3.0)                              (1.3)                                        

  Preoperative chemotherapy                                                                                                         0.003

      No                                            299\                               70\                                          
                                                    (98.4)                             (90.9)                                       

      Yes                                           5\                                 7\                                           
                                                    (1.6)                              (9.1)                                        

  Cytoreduction                                                                                                                     0.046

      Optimal                                       235\                               49\                                          
                                                    (77.3)                             (63.6)                                       

      Suboptimal                                    60\                                25\                                          
                                                    (19.7)                             (32.5)                                       

      Unknown                                       9\                                 3\                                           
                                                    (3.0)                              (3.9)                                        

  Postoperative chemotherapy                                                                                                        0.001

      Triweekly                                     216\                               69\                                          
                                                    (71.1)                             (89.6)                                       

      Dose dense                                    88\                                8\                                           
                                                    (28.9)                             (10.4)                                       

  Bevacizumab exposure                                                                                                              

      Mean No. of cycles (range)                    --                                 7.9\                                         --
                                                                                       (1--17)                                      

      Mean dose (mg/kg) (range)                     --                                 9.2\                                         
                                                                                       (7.5--15.1)                                  

  PFI                                                                                                                               0.354

      ≥12 months (platinum-sensitive)               160\                               33\                                          
                                                    (52.6)                             (42.9)                                       

      6--12 months (partially platinum-sensitive)   54\                                17\                                          
                                                    (17.8)                             (22.1)                                       

      \<6 months (platinum-resistant)               90\                                27\                                          
                                                    (29.6)                             (35.1)                                       

  Progression                                       156\                               45\                                          
                                                    (51.3)                             (58.4)                                       

  Death                                             114\                               22\                                          
                                                    (37.5)                             (28.6)                                       
  -------------------------------------------------------------------------------------------------------------------------------------------

*Chemotherapy regimen was referred to paclitaxel-carboplatin doublets*.

*Data was analyzed by X^2^ or Fisher\'s exact test*.

*SD, standard deviation; PFI, progression-free interval*.

### Cohort 2 Patients

Sixty-five patients with relapsed or persistent disease (mean age, 52.5 ± 11.0 y; range, 18--74 y) were enrolled. Patients\' baseline characteristics are shown in [Table 2](#T2){ref-type="table"}. Of those treated with various chemotherapy regimens, 39 (60.0%) received adjuvant platinum-based chemotherapy and 22 (33.8%) had prior BEV use. BEV dosage was 7.0--12.6 (mean, 9.5 ± 1.3) mg/kg and 7.9--11.6 (mean, 10.2 ± 1.1) mg/kg for patients with the first and ≥2 relapses, respectively; the number of treatment cycles was 1--22 (mean 5.3 ± 3.1) and 2--19 (mean 6.5 ± 4.4), respectively. The median follow-up period was 3.6 m (range 0.1--37.3 m). Most patients (*n* = 60, 92.3%) were diagnosed with EOC; 2 (3.1%) and 3 (4.6%) were diagnosed with TC and PPC, respectively. Thirty-nine patients (60.0%) had serous histology, 10 (15.4%) had CCC histology, 6 (9.2%) had endometrioid histology, and 4 (6.2%) had mucinous histology. The other histological types included transitional cell carcinoma and poorly-differentiated adenocarcinoma. During follow-up, 39 patients (60.0%) developed progressive disease, and 29 (44.86%) died.

###### 

Clinico-pathological characteristics of patients with recurrent or persistent disease (Cohort 2) (*N* = 65).

  ------------------------------------------------------------------------------------------------------------------------------------------
                                      **Platinum-resistant (PFI \< 6 m) *N* = 21**   **Platinum-sensitive (PFI ≥ 6 m) *N* = 44**   ***P***
  ----------------------------------- ---------------------------------------------- --------------------------------------------- ---------
  Age (mean ± SD)                     53.7 ± 7.8                                     51.9 ± 12.2                                   0.536

  Cancer origin                                                                                                                    0.682

      Ovary                           10\                                            40\                                           
                                      (95.2)                                         (91.0)                                        

      Tube                            --                                             2\                                            
                                                                                     (4.5)                                         

      Peritoneum                      1\                                             2\                                            
                                      (4.8)                                          (4.5)                                         

  Stage                                                                                                                            

      I                               --                                             5\                                            --
                                                                                     (11.4)                                        

      II                              1\                                             4\                                            
                                      (4.8)                                          (9.1)                                         

      III                             12\                                            28\                                           
                                      (57.1)                                         (63.6)                                        

      IV                              8\                                             7\                                            
                                      (38.1)                                         (15.9)                                        

  Histology                                                                                                                        0.386

      Serous                          11\                                            28\                                           
                                      (52.4)                                         (63.6)                                        

      Non-serous                      10\                                            16\                                           
                                      (47.6)                                         (36.4)                                        

          Clear cell                  --                                             2\                                            
                                                                                     (4.5)                                         

          Endometrioid                2\                                             4\                                            
                                      (9.5)                                          (9.1)                                         

          Mucinous                    8\                                             4\                                            
                                      (38.1)                                         (9.1)                                         

          Other type                  --                                             6\                                            
                                                                                     (13.6)                                        

  Tumor grade                                                                                                                      --

      Low (grade 1)                   --                                             2\                                            
                                                                                     (4.5)                                         

      High (grade 2 or 3)             21\                                            40\                                           
                                      (100)                                          (91.0)                                        

      Unknown                         --                                             2\                                            
                                                                                     (4.5)                                         

  Primary cytoreduction                                                                                                            0.568

      Optimal                         13\                                            31\                                           
                                      (61.9)                                         (70.5)                                        

      Suboptimal                      7\                                             12\                                           
                                      (33.3)                                         (27.3)                                        

      Unknown                         1\                                             1\                                            
                                      (4.8)                                          (2.3)                                         

  PFI after first-line chemotherapy                                                                                                --

      \<6 months                      21\                                            --                                            
                                      (100)                                                                                        

      6--12 months                    --                                             21\                                           
                                                                                     (47.7)                                        

      ≥12 months                      --                                             23\                                           
                                                                                     (52.3)                                        

  Chemotherapy regimen                                                                                                             

      PTX-platinum (Triweekly)        3\                                             11\                                           
                                      (14.3)                                         (25.0)                                        

      PTX-platinum (Dose dense)       2\                                             5\                                            
                                      (9.5)                                          (11.4)                                        

      PLD                             8\                                             3\                                            
                                      (38.1)                                         (6.8)                                         

      PLD--platinum                   6\                                             16\                                           
                                      (28.6)                                         (36.4)                                        

      GEM (Dose dense)                --                                             2\                                            
                                                                                     (4.5)                                         

      GEM--platinum                   1\                                             2\                                            
                                      (4.8)                                          (4.5)                                         

      Topotecan                       --                                             3\                                            
                                                                                     (6.8)                                         

      Topotecan (Dose dense)          1\                                             --                                            
                                      (4.8)                                                                                        

      Cyclophosphamide--platinum      --                                             1\                                            
                                                                                     (2.3)                                         

  Next progression                                                                                                                 0.194

      No                              6\                                             20\                                           
                                      (28.6)                                         (45.5)                                        

      Yes                             15\                                            24\                                           
                                      (71.4)                                         (54.5)                                        
  ------------------------------------------------------------------------------------------------------------------------------------------

*PFI, progression-free interval; PTX, paclitaxel; PLD, pegylated liposomal doxorubicin; GEM, gemcitabine*.

Relationships between PFI \<6 or ≥6 m and clinicopathological factors are presented in [Table 2](#T2){ref-type="table"}. No statistical difference between PFI of 6 m and stage, histology, tumor grade, residual tumor size during primary surgery, or next disease progression was observed.

Clinical Outcomes
-----------------

### Cohort 1 Patients With Advanced-Stage Disease

Survival curves for 234 patients stratified by means of BEV added to chemotherapy or chemotherapy alone are illustrated in [Figure 2](#F2){ref-type="fig"}. The median PFS duration was greater in the subgroup with chemotherapy plus BEV than with chemotherapy alone (11.6 vs. 9.3 m, *P* = 0.325; HR 0.84, 95% CI, 0.6--1.19) among advanced-stage patients ([Figure 2A](#F2){ref-type="fig"}), similar to that found among the high-risk patients (10.5 vs. 6.0 m, *P* = 0.035; HR 0.62, 95% CI, 0.39--0.97) ([Figure 2B](#F2){ref-type="fig"}). The median OS was not achieved in the subgroup with BEV and was 43.7 m in those without BEV (*P* = 0.123; HR 0.69, 95% CI, 0.43--1.11) among advanced-stage patients ([Figure 2A](#F2){ref-type="fig"}); similar results were seen among the high-risk patients (not reached versus 34.7 m, *P* = 0.101; HR 0.61, 95% CI, 0.33--1.10) ([Figure 2B](#F2){ref-type="fig"}).

![Progression-free and overall survival in **(A,C)** stage III--IV patients and **(B,D)** high-risk patients undergoing first-line therapy, tested by the log-rank test. **(A,B)** between chemotherapy (Chemo) with and without bevacizumab (BEV); **(C,D)** between Chemo with BEV throughout, BEV initiation, and Chemo alone.](fonc-10-01095-g0002){#F2}

Compared to patients with chemotherapy alone, among the high-risk patients, patients with BEV throughout had a significantly greater PFS (17.6 m; *P* = 0.005; HR 0.39, 95% CI, 0.20--0.75) and OS (not reached; *P* = 0.010; HR 0.22, 95% CI, 0.07--0.72) ([Figure 2D](#F2){ref-type="fig"}). However, among advanced-stage patients, patients with BEV throughout had a significantly greater OS (not reached; *P* = 0.030; HR 0.41, 95% CI, 0.18--0.93), but not PFS, than those with chemotherapy alone ([Figure 2C](#F2){ref-type="fig"}).

Advanced-stage patients treated with chemotherapy plus BEV in the subgroup of PFI \<6 m had a significantly greater PFS (*P* = 0.001), but not OS ([Figure 3B](#F3){ref-type="fig"}) when compared to those treated with chemotherapy alone; no statistical difference in PFS or OS was observed in the subgroup of PFI ≥ 6 m ([Figure 3A](#F3){ref-type="fig"}). No statistical difference in the impacts of BEV on PFS or OS between clear cell and serous histology was observed in the early or advanced stage ([Supplementary Figure 1](#SM2){ref-type="supplementary-material"}).

![Progression-free and overall survival between paclitaxel-carboplatin chemotherapy (Chemo) with and without bevacizumab (BEV) in stage III--IV patients undergoing first-line therapy were tested using the log-rank test **(A)** in the progression-free interval (PFI) ≥6 m subgroup and **(B)** in the PFI \<6 m subgroup.](fonc-10-01095-g0003){#F3}

### Cohort 2 With Relapsed or Persistent Disease

The survival curves stratified by PFI of 6 and 12 m are illustrated in [Figure 4](#F4){ref-type="fig"}. Patients with PFI ≥6 m after primary therapy had a significantly better OS and PFS2-PFS than those with PFI \<6 m (*P* \< 0.001 and *P* \< 0.001, respectively) ([Figure 4A](#F4){ref-type="fig"}). Patients with a longer PFI had more favorable survival. Patients with PFI ≥12 m had greater OS and PFS2-PFS than those with PFI \<6 m (*P* \< 0.001 and *P* \< 0.001, respectively) ([Figure 4B](#F4){ref-type="fig"}).

![Progression-free survival 2 (PFS2)-PFS and overall survival in patients with relapsed/persistent disease treated with bevacizumab (BEV) ± chemotherapy (Chemo), stratified by **(A)** progression-free interval (PFI) \< and ≥6 m; **(B)** PFI \<6, 6--12, and ≥12 m, tested by the log-rank test.](fonc-10-01095-g0004){#F4}

Univariate and Multivariate Analyses
------------------------------------

In the univariate analysis, residual nodules ≥1 cm and PFI \<6 m were significantly associated with a high risk of death and disease progression in Cohort 1 patients with advanced disease [Table 3](#T3){ref-type="table"}. Age ≥53 years was associated with a high risk of death due to cancer. In a multivariate-adjusted model, PFI \<6 m was the strongest predictor of disease progression (HR 27.78, 95% CI 15.87--47.62) and death (HR 5.92, 95% CI 3.82--9.17) ([Table 4](#T4){ref-type="table"}). BEV throughout and optimal cytoreduction in the front-line setting were independent predictors of reduced cancer progression (HR 0.43, 95% CI 0.25--0.73, and HR 0.63, 95% CI 0.44--0.90, respectively). Although BEV throughout was a predictor of cancer death, its impact was influenced by confounders in the multivariate analysis.

###### 

Univariate analysis in newly diagnosed cancer patients with stage III and IV disease (*n* = 234).

  **Univariate analysis**                                                                                                                                                                           
  ----------------------------- ------- ------------------------ ----------------------------------------- --------------------------------- ------------------ ----------------------------------- ---------------------------
  **Variable**                  **N**   **Progression events**   **Median time to progression (months)**   **HR for progression (95% CI)**   **Death events**   **Median time to death (months)**   **HR for death (95% CI)**
  Age (years)                                                                                                                                                                                       
      \<53                      99      78                       9.8                                       1.00                              40                 55.1                                1.00
      ≥53                       135     88                       10.8                                      0.87 (0.64--1.18)                 71                 39.9                                1.51 (1.02--2.23)
  Histology                                                                                                                                                                                         
      Non-serous                57      40                       7.0                                       1.00                              25                 36.3                                1.00
      Serous                    177     126                      11.07                                     0.84 (0.54--1.32)                 86                 47.0                                0.78 (0.55--1.12)
  Tumor grade                                                                                                                                                                                       
      Low                       7       3                        9.80                                      1.00                              0                  --                                  1.00
      High                      227     162                      10.5                                      1.78 (0.57--5.60)                 111                33.2                                21.32 (0.21--2146.94)
  Pre-operative chemotherapy                                                                                                                                                                        
      No                        223     161                      10.5                                      1.00                              106                47.0                                1.00
      Yes                       11      5                        17.0                                      0.74 (0.30--1.80)                 5                  22.1                                1.83 (0.74--4.52)
  Cytoreduction                                                                                                                                                                                     
      Optimal                   150     97                       15.7                                      1.00                              65                 54.1                                1.00
      Suboptimal                84      69                       5.4                                       2.25 (1.65--3.08)                 46                 33.7                                1.77 (1.21--2.60)
  Post-operative chemotherapy                                                                                                                                                                       
      Triweekly                 163     114                      10.3                                      1.00                              66                 46.7                                1.00
      Dose dense                71      52                       11.0                                      0.93 (0.67--1.29)                 45                 45.6                                1.17 (0.80--1.72)
  PFI                                                                                                                                                                                               
      ≥6 months                 145     94                       17.6                                      1.00                              55                 63.0                                1.00
      \<6 months                89      72                       1.9                                       21.48 (13.64--33.85)              56                 23.6                                6.11 (4.07--9.17)
  Bevacizumab                                                                                                                                                                                       
      No                        167     122                      9.3                                       1.00                              90                 43.7                                1.00
      Initiation                37      26                       10.5                                      0.99 (0.65--1.53)                 15                 --                                  0.95 (0.55--1.64)
      Throughout                30      18                       17.5                                      0.69 (0.42--1.13)                 6                  --                                  0.41 (0.18--0.93)

*Chemotherapy regimen was referred to paclitaxel-carboplatin doublets*.

*HR, hazard ratio; PFI, progression-free interval*.

###### 

Multivariate analysis in newly diagnosed cancer patients with stage III and IV disease (*n* = 234).

  **Multivariate analysis**                                                                 
  ------------------------------------------------------- --------------------------------- ---------------------------
  **Variable**                                            **HR for progression (95% CI)**   **HR for death (95% CI)**
  Age (≥ 53 vs \<53 years)                                0.98 (0.71--1.37)                 1.45 (0.96--2.19)
  Histology (serous vs non-serous)                        0.96 (0.63--1.46)                 1.17 (0.73--1.89)
  Cytoreduction (suboptimal vs optimal)                   1.58 (1.11--2.26)                 1.08 (0.72--1.62)
  Post-operative chemotherapy (dose dense vs triweekly)   1.03 (0.72--1.46)                 0.86 (0.57--1.30)
  PFI (\<6 vs ≥ 6 months)                                 27.78 (15.87--47.62)              5.92 (3.82--9.17)
  Bevacizumab (throughout vs no)                          0.43 (0.25--0.73)                 0.43 (0.19--1.02)

*Chemotherapy regimen was referred to paclitaxel-carboplatin doublets*.

*HR, hazard ratio; PFI, progression-free interval*.

By cox proportional analysis in Cohort 2 patients, those with PFI of ≥6 m after primary therapy had significantly lower risks of death (HR 0.22, 95% CI 0.10--0.50) and next progression (HR 0.17, 95% CI 0.08--0.39) than those with PFI \<6 m.

Safety Assessment
-----------------

In total, 142 (77 Cohort 1 and 65 Cohort 2) patients were assessed for AEs ([Table 5](#T5){ref-type="table"}). Most AEs were mild (≤ grade 2), treatable, and reversible. Commonly observed AEs ≥ grade 3 included neutropenia (*n* = 44, 31.0%), febrile neutropenia (*n* = 12, 8.4%), anemia (*n* = 6, 4.2%), diarrhea (*n* = 2, 1.4%), and anorexia (*n* = 1, 0.7%). BEV-associated AEs were not observed. All cases of non-CNS bleeding (*n* = 26, 3.5%), hypertension (*n* = 21, 14.8%), proteinuria (*n* = 13, 9.2%), or venous thromboembolic events (*n* = 3, 2.1%) were rare and treatable in patients with or without prior BEV use.

###### 

Adverse effects and grades in ovarian/tubal/peritoneal patients treated with bevacizumab plus chemotherapy (*N* = 142).

                           **Front-line therapy with bevacizumab** ***n*** **=** **77**   **Relapse therapy without prior bevacizumab** ***n*** **=** **43**   **Relapse therapy with prior bevacizumab** ***n*** **=** **22**                                                                                             
  ------------------------ -------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------- --------- ----------- ----------- ---------- --------- ----------- ----------- ---------- ----
  Bleeding (non-CNS)                                                                                                                                                                                                                                                                                                       
      Nasal                8 (10.4)                                                       --                                                                   --                                                                --        4 (9.3)     --          --         --        2 (9.1)     --          --         --
      Gingival             3 (3.9)                                                        --                                                                   --                                                                --        --          --          --         --        2 (9.1)     --          --         --
      Conjunctival         --                                                             --                                                                   --                                                                --        1 (2.3)     --          --         --        --          --          --         --
      Gastrointestinal     3 (3.9)                                                        --                                                                   --                                                                --        1 (2.3)     1 (2.3)     --         --        1 (4.5)     --          --         --
  Hypertension             7 (9.1)                                                        3 (3.9)                                                              4 (5.2)                                                           --        1 (2.3)     4 (9.3)     --         --        1 (4.5)     1 (4.5)     --         --
  Proteinuria              10 (13.0)                                                      --                                                                   --                                                                --        3 (7.0)     --          --         --        --          --          --         --
  Wound disruption         4 (5.2)                                                        --                                                                   --                                                                --        --          --          --         --        1 (4.5)     --          --         --
  Venous thromboembolism   2 (2.6)                                                        --                                                                   --                                                                --        --          1 (2.3)     --         --        --          --          --         --
  Febrile neutropenia      --                                                             --                                                                   7 (9.1)                                                           --        --          --          3 (7.0)    --        --          --          2 (9.1)    --
  Neutropenia              19 (24.7)                                                      7 (9.1)                                                              28 (36.4)                                                         1 (1.3)   15 (34.9)   1 (2.3)     8 (18.6)   1 (2.3)   6 (27.3)    3 (13.6)    6 (27.3)   --
  Anemia                   34 (44.2)                                                      18 (23.4)                                                            3 (3.9)                                                           --        16 (37.2)   10 (23.3)   3 (7.0)    --        8 (36.4)    5 (22.7)    --         --
  Nausea                   36 (46.8)                                                      2 (2.6)                                                              --                                                                --        20 (46.5)   2 (4.7)     --         --        9 (40.9)    --          --         --
  Vomiting                 12 (15.6)                                                      2 (2.6)                                                              --                                                                --        11 (25.6)   4 (9.3)     --         --        2 (9.1)     --          --         --
  Mucositis                18 (23.4)                                                      --                                                                   --                                                                --        15 (34.9)   4 (9.3)     --         --        6 (27.3)    --          --         --
  Diarrhea                 7 (9.1)                                                        2 (2.6)                                                              1 (1.3)                                                           --        4 (9.3)     --          --         --        3 (13.6)    1 (4.5)     1 (4.5)    --
  Constipation             35 (45.5)                                                      3 (3.9)                                                              --                                                                --        14 (32.6)   --          --         --        13 (59.1)   1 (4.5)     --         --
  Anorexia                 32 (41.6)                                                      2 (2.6)                                                              1 (1.3)                                                           --        14 (32.6)   3 (7.0)     --         --        11 (50.0)   1 (4.5)     --         --
  Paresthesia              45 (58.4)                                                      22 (28.6)                                                            --                                                                --        23 (53.5)   8 (18.6)    --         --        12 (54.5)   9 (40.9)    --         --
  Alopecia                 2 (2.6)                                                        62 (80.5)                                                            --                                                                --        5 (11.6)    29 (67.4)   --         --        1 (4.5)     18 (81.8)   --         --

*Data was shown as n (%)*.

*Grades of adverse effects were assessed according to the Common Terminology Criteria for Adverse Events*.

*CNS, central nervous system*.

*Nasal bleeding occurred after 2 to 5 cycles of chemotherapy plus bevacizumab*.

*The following adverse effects did not occur in our participants: Left ventricular systolic dysfunction, congestive heart failure, fistula/abscess, gastrointestinal perforation, reversible posterior leukoencephalopathy syndrome, or arterial thromboembolism*.

Discussion {#s4}
==========

We found improved PFS as a benefit of BEV throughout triweekly in the dosage range of 7.5--15 mg/kg, which is consistent with results of independent phase 3 trials assessing front-line therapy ([@B7], [@B8]) and real-world data ([@B15]--[@B17]). PFI \<6 m independently predicted shorter PFS and OS, but BEV may reduce platinum-resistant relapse; these findings are in concordance with the prospective single-arm results in JGOG3022 ([@B17]). Moreover, to our knowledge, this is the first real-world study to provide data on improved OS as an advantage of BEV throughout, relative to chemotherapy alone, in front-line therapy in advanced-stage EOC patients and the high-risk subgroup.

The GCIG considered PFS as the primary endpoint in front-line therapy for ovarian cancer, and not OS, because of the confounding effects of post-progression therapy on OS ([@B7], [@B22]). Advances in various post-progression therapies, such as BEV ([@B11]--[@B14], [@B18]), trientine ([@B23]), and poly(adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitor ([@B4], [@B24]--[@B26]), may help extend patients\' lives. We provided evidence while we observed a longer median OS in the BEV throughout group compared to that in GOG-218 and ICON7, even in patients who received only chemotherapy. When adjusted by multivariate analysis, our real-world findings corresponded to the GCIG consensus and emphasized the role of BEV throughout in PFS prolongation. This phenomenon is observed in the improved OS after using BEV in relapsed EOC, specifically in the platinum-sensitive subgroup.

A significantly improved PFS when adding olaparib after a response to chemotherapy plus BEV has occurred and a higher incidence of reversible grade ≥ 3 haematologic AEs were reported in the PAOLA-1 trial ([@B27]). Tewari et al. reported the reductions in risk of death for BRCA1/2-mutated or non-BRCA1/2 homologous recombination deficient (HRD) carcinomas when compared to the wild type ([@B9]). However, BRCA/HRD testing was not predictive of BEV activity. Our patients had a shorter median PFS than that of the non-Olaparib arm in PAOLA-1 trial ([@B27]) or those in real-world studies ([@B15]--[@B17]). The reason for these discrepancies may be multifactorial, including different study designs, shorter maintenance duration or lower dosage of BEV, more complex disease, or reimbursement issues in the real-world setting.

Platinum resistance is an indicator of poor prognosis, and its involved mechanism is complex ([@B28]--[@B30]). Lee et al. reported that the effectiveness of BEV-included chemotherapy was feasible but varied according to the chemotherapy partner in platinum-resistant EOC ([@B20]). A real-world small study showed PFS benefits of early BEV-added chemotherapy, but insignificant survival differences between platinum-resistant and -sensitive recurrent EOC ([@B31]). However, we provided more favorable oncologic outcomes of BEV-added relapse therapy in platinum-sensitive patients. Furthermore, CCC has been thought of as a platinum-resistant malignancy. The histological distribution of EOC in Asia is quite different from that in the West. Serous, endometrioid, and CCC histology constituted 40--50, 15--20, and 15--20%, respectively, of EOC in Taiwan from 2000--2008 ([@B32]). Early-stage patients with CCC or grade 3 tumor were included in ICON7 trial as a subgroup of particular interest ([@B8]). Our early-stage patients used BEV following ICON7 inclusion criteria. Komiyama et al. reported that BEV-added front-line therapy was effective for advanced-stage clear cell carcinoma ([@B17]). However, the lack of benefits of BEV on clinical outcomes across different histologies in our study is similar to findings recorded in the ICON7 final results ([@B10]). Therefore, BEV could be applied regardless of histology in either an early or advanced stage.

Haematologic AEs were the most common in BEV-included trials in EOC ([@B7], [@B8], [@B11]--[@B14]), while similar results were observed in our study. Its safety was also promising in our relapse therapy. The cumulative incidences of hypertension and proteinuria were associated with median cumulative BEV dosages ([@B33]) or the treatment durations ([@B17]) in Asian women. However, our patients had less BEV-specific incidences and lower grades of AEs. This may be related to lower dosages, or fewer treatment cycles in most patients, which were in concordance with lower incidence rates of hypertension, proteinuria, GI, or non-CNS bleeding events in the BEV throughout arm in ICON7 than that in GOG-218 ([@B7], [@B8]).

A study carried out in Belgium reported the relatively high cost-effectiveness of BEV with the most promising results in front-line treatment of stage IV EOC patients ([@B34]). The prognostic factors, e.g., advanced stage, histology, pre- and post-operative chemotherapy, and residual tumor size, were adjusted for during multivariate analysis, but expert-patient SDM regarding BEV utilization may possibly be influenced by choices of post-progression therapy or socio-economic factors which were not included in our analysis.

There are some other limitations to our study. BEV and BRCA/HRD testing has not yet been covered by our NHI. Hence, we are unable to provide real-world data regarding BEV in patients with BRCA mutation/HRD. Although most AEs were mild and treatable, the number of patients treated with BEV after prior BEV is too small to draw a conclusion in our relapsed cohort. Further research should be conducted to clarify these questions.

In conclusion, adding BEV to traditional front-line or relapse therapy was safe in EOC. This strategy as maintenance therapy was effective in extending PFS and OS in advanced-stage patients. Platinum-sensitivity was the strongest prognostic factor. Platinum-sensitive relapsed EOC patients treated with BEV-added chemotherapy had a significant improvement in OS and had a longer duration in progressing to the next progression.
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